Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues
We are witnessing a paradigm shift in drug development and clinical practice to fight the novel coronavirus disease (COVID-19), and a number of clinical trials have been or are being testing various pharmacological approaches to counteract viral load and its complications such as cytokine storm. How...
Saved in:
Main Authors: | Milo Gatti (Author), Eleonora Turrini (Author), Emanuel Raschi (Author), Piero Sestili (Author), Carmela Fimognari (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness?
by: Piero Sestili, et al.
Published: (2020) -
Itch and Janus Kinase Inhibitors
by: Yujin Han, et al.
Published: (2023) -
Janus kinase inhibitors: jackpot or potluck?
by: Pavithran Keechilat, et al.
Published: (2012) -
Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
by: Fabienne Ballanger, et al.
Published: (2023) -
Janus Kinase inhibitors in dermatology: a review
by: Bárbara Vieira-Granja, et al.
Published: (2023)